Genomenon is a leading genomic intelligence company dedicated to improving the quality of patients’ lives by uncovering the genomic drivers of genetic disease and cancer. Blending the power of AI with genomic expertise, Genomenon simplifi es complex genetic data into actionable insights for patient diagnosis and precision medicine development. With a goal to curate the entire genome within the next several years, Genomenon partners with leading clinical diagnostic labs and precision therapeutic companies to improve rare disease diagnoses, and de-risk the development of targeted therapies with AI-powered genomic evidence curation.
Genomenon, a name signifying “born out of need” in ancient Greek, perfectly encapsulates the genesis of the company’s journey.
In his clinical practice and genomic research, co-founder Dr. Mark Kiel was frustrated with the painfully slow and time-consuming process of manual curation. He was also aware of the diagnostic odyssey that thousands of rare disease patients and families face as he and his twin brother had hypodontia, or missing adult teeth, in their youth. Living with a rare condition as a child focused Mark’s attention on genetics, and his desire to make an impact on rare diseases.
Genomenon was founded in 2014 to address this pressing need for faster, more comprehensive variant interpretation by combining expert curation with unique machine-learning methods designed to keep up with the pace of new publications and present the most relevant information to researchers.
Today, Genomenon’s global team of experts are simplifying genetic data into actionable insights for customers all over the world through their offerings of software, data, and services.
